RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction
about
Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature.Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.Longitudinal change in clinical fracture incidence after initiation of bisphosphonatesNew laboratory tools in the assessment of bone quality.Efficacy of ibandronate: a long term confirmation.Osteoporosis therapies: evidence from health-care databases and observational population studies.Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis: from a national health insurance claims database.Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendationsComparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.Progress in osteoporosis and fracture prevention: focus on postmenopausal women.Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort studyClinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.Fractures and mortality in relation to different osteoporosis treatments.Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on "real-world" data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database
P2860
Q30611728-38D49FD5-ADD6-4228-8D48-170E7D35A866Q33818302-48EBE37D-88D9-4D29-9FF2-8B089AEBB2E9Q33819111-17B111CB-A69A-4B05-AC28-01C3BC784858Q33828962-49B23B06-4D5A-4097-A452-76205BE4026EQ33965657-5578B34B-3A7D-48AF-BDD9-7D722642776CQ34242906-48040153-2E51-4E16-A791-C67187E868B1Q35647883-F5825A71-99AB-45DB-ADD2-75ED2D876F15Q35678676-FD48E099-3F1E-4E98-BF8B-614F2E0DCC1AQ35693057-DDC40A21-C426-4E76-8C23-A547841EB87CQ37402282-CE99F837-779B-4335-88FF-5B0D3A079177Q37453973-DD3CCC2C-CCA7-4759-8334-4F7F6B659C65Q37701830-B7166D36-1969-4A48-B729-6EF9E55F06C0Q37862933-ACA5961B-837B-4B3B-BA22-9DB50736E868Q42108489-4F938B07-26F5-47CB-B3AE-113B6730519CQ43166707-B6179CC2-1658-4AA6-B053-1721F7EB8F8CQ43577539-7A131D6E-1190-4918-A61C-304242956234Q44381104-1BD7C80E-69A8-45EA-B2E7-8A246CE84BA8Q44574043-57608783-8C14-4904-B15D-8926FC0E6590Q46244082-03561A70-566F-401D-A909-A20EE4701C4BQ57816528-4532B014-EF17-4D68-B675-8D1D1C103C2F
P2860
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RisedronatE and ALendronate In ...... ces in fracture risk reduction
@en
RisedronatE and ALendronate Intervention over Three Years
@nl
type
label
RisedronatE and ALendronate In ...... ces in fracture risk reduction
@en
RisedronatE and ALendronate Intervention over Three Years
@nl
prefLabel
RisedronatE and ALendronate In ...... ces in fracture risk reduction
@en
RisedronatE and ALendronate Intervention over Three Years
@nl
P2093
P2860
P1476
RisedronatE and ALendronate In ...... ces in fracture risk reduction
@en
P2093
P2860
P2888
P304
P356
10.1007/S00198-008-0772-2
P407
P577
2008-10-23T00:00:00Z